SEC Form 4 · accession 0001562180-16-001395
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Robichaud
Officer — Chief Scientific Officer
Period of report
Jan 25, 2016
Accepted (ET)
Jan 26, 2016 · 2:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 25, 2016 | S | 20,000 | $40.02 | D | 162,222 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $40.00 USD to $40.13 USD. The price reported above reflects the weighted average sale price.